Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644792 | 1.00 | FUCA1 (0.60) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL14986453 | 0.87 | FUCA1 (0.51) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL16740670 | 0.87 | FUCA1 (0.51) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL14986672 | 0.87 | FUCA1 (0.51) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL16714621 | 0.87 | FUCA1 (0.51) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL30014513 | 0.87 | FUCA1 (0.71) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL4503331 | 0.84 | GBA1 (0.49) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL4506217 | 0.84 | GBA1 (0.49) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL500415 | 0.84 | GBA1 (0.49) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL4503332 | 0.84 | GBA1 (0.49) | FUCA1SIGMAR1S1PR1S1PR5ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | FUCA1 4292/4885SIGMAR1 3224/4885S1PR1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.